Joint Sputnik V and AstraZeneca trials are underway in the United Arab Emirates, Azerbaijan and Argentina. (file)
New Delhi:
The Sputnik V team confirmed on Wednesday that the temporary delay in delivery due to production scale will be fully resolved in August.
“The Sputnik V team confirms that the temporary second ingredient delivery delay due to a massive increase in vaccine production capacity will be fully resolved in August,” it said in a press release.
Noting the doubling of Sputnik V’s capacity in September, the release said, “Sputnik V has forged production partnerships with producers in 14 countries and will additionally double its capacity in September, the Serum Institute said. Thank you for our partnership with top producers including of India, the world’s largest vaccine producer.”
In addition, the release states that a study published by the Gamleya Center Vaccines International Medical Journal showed that Sputnik is one of the most efficient vaccines against coronavirus variants including V delta.
“Sputnik V is in high demand worldwide due to its exceptional efficacy and safety, as well as the absence of any serious side effects that have been linked to the use of some other vaccines. In countries where Sputnik V is used nationally Vaccination campaigns, especially in Argentina and Mexico, have seen a steady decline in COVID-19 cases,” it read.
In addition, the release noted the role of Sputnik V in vaccine combination (mix and match approach), and stated, “Sputnik V, which has resulted in heterogeneous boosting (“vaccine cocktail”) using two different adenoviral vectors (Ad5 and Ad26). “) pioneered the approach. For two separate shots, the first was offered to AstraZeneca on November 23, 2020, when the second producer was offered a joint mix and match trial.”
Joint Sputnik V and AstraZeneca trials have been underway since February 2021 in the United Arab Emirates, Azerbaijan and Argentina. The initial positive results were declared on July 30. More positive results on immunogenicity are expected this week.
“Sputnik V will accelerate work with other vaccine producers on the mix and match approach, which triggers a stronger and longer-lasting immune response. The first component of Sputnik V (Sputnik Light) that on its own has been shown to reduce the risk of infection by over 80%.” Many two-shot vaccines, which have demonstrated greater efficacy, will be offered to other vaccine producers as part of our mix and match strategy,” the release noted.
Team Sputnik V also denied media reports and said that no country has canceled the contract for the delivery. “In contrast, demand for Sputnik V continues to increase significantly due to its exceptional safety and efficacy, as demonstrated through this,” he said.
(Except for the title, this story has not been edited by NDTV staff and is published from a syndicated feed.)
.